Medicinal and nutraceutical formulations based on Chaga mushrooms, chemical compounds and pharmaceutical compositions, and methods of production. When administered to a human or animal, the formulations, compounds, and pharmaceutical compositions are useful for the treatment of diseases such as cancers. The nutraceutical formulation includes a reduction of Chaga mushroom, where the reduction is formed in a reduction solvent; and an extraction of Chaga mushroom, where the extraction is formed in an extraction solvent. The reduction and extraction are mixed together or combined in accordance with methods known to those skilled in the art, to form the nutraceutical formulation. The medicinal formulation is a reaction product made by preparing a Chaga mushroom reduction in a reduction solvent under pressure, preparing a Chaga mushroom extraction in an extraction solvent, mixing or combining the Chaga reduction with the Chaga extraction, mixing or combining the Chaga formulation with an esterification mixture containing proline, fructose, and a fatty acid for the development of esterified compounds, and including sources of sugar esters capable of emulsion within otherwise non-miscible liquid compounds, or a predetermined amount of Manuka honey sufficient to cause esterification and facilitate emulsion at a temperature capable of inducing a reaction between the constituents of the Chaga mushroom with the constituents of the esterification mixture or Manuka honey, and combining that heterogenous mixture with medium chain triglyceride oil.

Provided herein is a compound of Formula (I-I) ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g., in the treatment of CNS-related disorders.

Compounds of formula (I):

##STR00001##

wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein are able to rescue dysfunctional mitochondria and are therefore of use in the treatment and prevention of neurodegenerative disorders as well as acute radiation syndrome and myalgic encephalomyelitis (ME, chronic fatigue syndrome) or post viral syndrome, including chronic symptoms arising from infection with SARS-CoV2 (long COVID).

Provided herein is a compound of Formula (I-I)

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g., in the treatment of CNS-related disorders.

The present invention relates to the technical field of pharmaceutics, and in particular to a triptolide lignocerate, a liposome thereof and a preparation method therefor. The chemical structural formula of the triptolide lignocerate is represented by formula (I). The triptolide lignocerate provided by the present invention is obtained by esterification of triptolide C14-OH and lignoceric acid. The anti-tumor effectiveness, safety and the like of the triptolide lignocerate liposome are further improved with respect to the prior art, so that a foundation is laid for providing safer and more effective triptolide-related clinical preparations. ##STR00001##